Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 197
Last updated 2018-07-05
Summary
Background:
* Individuals who demonstrate symptoms of Alzheimer s disease, such as progressive memory loss, may be eligible to participate in National Institutes of Health research studies. However, other physical and psychological conditions may produce symptoms similar to those of Alzheimer s disease. To determine whether a patient meets the eligibility criteria to participate in a research protocol, researchers must perform a series of diagnostic tests and procedures.
* These evaluations are designed to evaluate a participant s general medical condition (for example, blood tests and neurological exams) and to confirm a diagnosis or rule out an individual for consideration. They maximize the safety for participants in studies conducted at the National Institutes of Mental Health.
Objective:
\- To determine the eligibility of individuals for active Alzheimer s disease protocols.
Eligibility:
\- Individuals 45 years of age and older who have been having memory problems that have been getting worse with time and have been interfering with everyday life.
Design:
* Required tests and procedures for various research studies may include the following:
* Medical history and physical examination, including a psychiatric evaluation.
* Neuropsychological tests to test memory, mood, concentration, and thought processes.
* Blood and urine tests.
* Imaging studies (X-rays, magnetic resonance imaging (MRI), computerized tomography (CT), positron emission tomography (PET)).
* Additional blood samples and MRI data for future use.
* After all eligibility assessments are complete, participants may be offered participation in one or more research protocols
Conditions
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Principal Investigators
-
Robert B Innis, M.D. · National Institute of Mental Health (NIMH)
Eligibility
- Min Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Completion
- 2017-07-06
Countries
- United States
Study Locations
More Related Trials
-
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
NCT01951118 ·Status: COMPLETED ·Phase: PHASE4
-
Brain Imaging and Mental Disorders of Aging Intervention
NCT00267163 ·Status: COMPLETED ·Phase: PHASE4
-
Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
NCT03299062 ·Status: COMPLETED ·Phase: NA
-
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
NCT02811653 ·Status: UNKNOWN ·Phase: NA
-
A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease
NCT00291421 ·Status: COMPLETED
-
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923 ·Status: COMPLETED ·Phase: PHASE2
-
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome
NCT02854917 ·Status: COMPLETED
-
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment of Language and Memory in Patients With Alzheimer's Disease
NCT00593372 ·Status: COMPLETED ·Phase: PHASE1
-
Enhancing Consent for Alzheimer's Research
NCT00453544 ·Status: COMPLETED ·Phase: NA
-
Neuroelectrical Biomarkers for Alzheimer's Disease Stages
NCT01880151 ·Status: COMPLETED ·Phase: NA
-
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
NCT00149175 ·Status: COMPLETED
-
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
NCT01864655 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
NCT01009255 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
NCT02162251 ·Status: COMPLETED
-
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757 ·Status: RECRUITING
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
Corticolimbic Degeneration and Treatment of Dementia
NCT00768261 ·Status: COMPLETED ·Phase: PHASE4
-
A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease
NCT04137926 ·Status: UNKNOWN ·Phase: NA
-
Examining Neuroinflammation in AlzHeimer's
NCT03548883 ·Status: COMPLETED
-
Multicenter Trial of Prednisone in Alzheimer's Disease
NCT00000178 ·Status: COMPLETED ·Phase: PHASE3
-
The Mechanism of MicroRNAs Network in Alzheimer's Disease
NCT05055310 ·Status: COMPLETED
-
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
NCT03088956 ·Status: COMPLETED
-
Brain Imaging in Alzheimer's Disease
NCT00039702 ·Status: COMPLETED
-
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608 ·Status: COMPLETED ·Phase: PHASE4